Adaptimmune Therapeutics

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adaptimmune reports strong Q1 results, eyes market leadership with afami-cel

Adaptimmune Therapeutics shows strong performance and progress in Q1 2024.
Strengths lie in innovative therapies, financial stability, and clear development plans.
Challenges include managing debt impact, FDA processes, and successful product launches.
Opportunities exist in market leadership, upcoming presentations, and growth strategies.

Adaptimmune achieves commercial milestone with Tecelra launch, poised for growth

Adaptimmune's Q2 performance reflects a transformative phase as it transitions into a commercial-stage company with a strong financial position and a focus on innovative cell therapies.
While facing challenges in operational execution and revenue forecasting, the company's strategic strengths lie in its pioneering treatments, robust pipeline, and customer-centric approach.
By capitalizing on opportunities for market expansion, strategic partnerships, and operational optimization, Adaptimmune is poised to drive growth and establish itself as a key player in the cell therapy sector.

Adaptimmune targets breakeven by 2027 with strong sarcoma franchise

Adaptimmune Therapeutics is strategically positioned to achieve operating breakeven by 2027 through significant cost reductions and a focus on their sarcoma franchise with Tecelra and lete-cel.
The company's financial stability, positive trial results, and revenue targets indicate a strong growth trajectory and confidence in their business strategy.
While facing challenges in cost reduction and workforce restructuring, Adaptimmune Therapeutics has opportunities to capitalize on market expansion and product efficacy to drive future growth.
Overall, the company's performance in Q3 reflects a proactive approach to financial sustainability and market competitiveness in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June  04, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”).  Adaptimmune sold a total of 23,575,000 ADSs at a price to the public of $11.00 per ADS, including 3,075,000 ADSs pursuant to the exercise in full by the underwriters of their option to purchase additional ADSs at the public offering price.

Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares

Investors need to pay close attention to Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June  01, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”) at a price to the public of $11.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 3,075,000 ADSs at the public offering price. The gross offering size for this offering is expected to be $225.5 million, excluding any exercise of the underwriters’ option to purchase additional ADSs. All ADSs in this offering are being sold by Adaptimmune with net proceeds to be used to advance the development of Adaptimmune’s immunotherapies into and through clinical trials as well as for other general corporate purposes. This offering is expected to close on or about June 4, 2020, subject to customary closing conditions.

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

Adaptimmune prudently decided to take advantage of its soaring share price to raise capital.

Why Adaptimmune Therapeutics Stock Sank and Then Quickly Rebounded Today

Shares of Adaptimmune Therapeutics PLC ADAP, +127.77% tumbled 11% in premarket trading Monday, after the biopharmaceutical company focused on cancer treatments said it planned a public offering of 12.5 million shares.

Adaptimmune's stock tumbles after plans for public stock offering

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June  01, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price. All of the ADSs in the offering are to be sold by Adaptimmune, with net proceeds to be used to advance the development of Adaptimmune’s immunotherapies into and through clinical trials as well as for other general corporate purposes.

Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

Positive results from a handful of patients treated have bolstered confidence in the company's cell-based approach to cancer treatment.

Here's Why Adaptimmune Therapeutics Is Rocketing Higher Today

Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) shares were advancing strongly Friday following an updated clinical readout from the company.

Adaptimmune Shares Nearly Double On Promising Cancer T-Cell Therapy Data

Adaptimmune Therapeutics PLC (NASDAQ: ADAP) shares jumped on Friday after the company announced updated data from its early-stage clinical trial in patients with lung, head and neck cancers.

Adaptimmune Therapeutics Makes a Big Splash at ASCO

- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy -

SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer

Big pharma partners could help this cutting-edge cell-therapy company be successful in the future.

Where Will Adaptimmune Be in 5 Years?

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2020 Results - Earnings Call Transcript

Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) rose 1.3% in pre-market trading after the company reported Q1 results.

Recap: Adaptimmune Therapeutics Q1 Earnings

- Upfront payment of $50m received from Astellas and approximately $90m offering completed -

Adaptimmune Reports Q1 Financial Results

Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Adaptimmune Therapeutics PLC (ADAP) a New Strong Buy Stock

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April  28, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for Orphan Drug Designation for ADP-A2M4 for the treatment of soft tissue sarcomas.  

Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products

OrganiGram Holdings Inc.

Adaptimmune Therapeutics and OrganiGram Holdings are two penny stocks that may be worth the risk.

2 Penny Stocks That Could Make You Rich

Atreca

CRISPR Therapeutics

These three clinical-stage biotechs are all bargains after last month's marketwide downturn.

Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In March

Agenus

Gilead Sciences

Viking Therapeutics

These clinical-stage drugmakers could be a steal at current levels.

Top Pharma Stocks Under $5

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q4 2019 Results - Earnings Call Transcript

Anavex Life Sciences

BioXcel Therapeutics

Can these soaring biotech stocks keep climbing?

3 Biotech Stocks That Already Doubled This Year

Amarin Corporation Plc

Aphria

Bicycle Therapeutics Plc - ADR

Novavax

Puma Biotechnology

These top growth stocks could dramatically improve your financial wellbeing.

6 Healthcare Stocks That Could Make You Filthy Rich

Applied Therapeutics Inc

Kiniksa Pharmaceuticals Ltd

These three clinical-stage biotechs could all double in value before year's end.

3 Top Biotech Stocks to Buy in February

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb.  07, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American Depositary Shares (“ADSs”), which initially closed on January 24, 2020, have exercised in full their option to purchase an additional 3,150,000 of its ADSs at a price to the public of $4.00 per ADS, raising additional net proceeds of approximately $11.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. The option exercise closed on February 7, 2020.  

Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares

Is  (ADAP) Outperforming Other Medical Stocks This Year?

News for Adaptimmune Therapeutics Stock (ADAP)